On March 11, Jensen, who is also William R. Jewell Distinguished Kansas Masonic Professor and professor of pathology and laboratory medicine, anatomy and cell biology, cancer biology and molecular biosciences, focused on COVID-19.
We were recently presented with the new report from American Cancer Society1 showing the biggest annual decrease in cancer mortality, which was mainly due to decline in smoking, as well as improvements in early detection and treatment.
Having cancer as a Latino in the United States has important implications potentially related to risk of carcinogenesis, knowledge of cancer prevention, access to cancer screening, therapy timing and choices, and access to good supportive/palliative or survivorship care.
On December 10, 2019, Dr. William G. Kaelin, Jr, Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza officially received the title of Nobel Laureate in Medicine.
I write, again, compelled by emerging scientific facts regarding a serious systemic error of negligence on the part of the main American gynecological societies, AAGL and ACOG, and their member practitioners—though the problem I highlight here also affects overseas gynecological counterparts, specifically the RCOG in the United Kingdom.
Each year, the American Society of Clinical Oncology conducts its National Cancer Opinion Survey to better understand Americans' views on a wide range of cancer-related issues and uncover areas that need to be addressed.
This year in the United States, nearly 270,000 women will receive the devastating news that they have breast cancer. Many will choose breast-conserving surgery, commonly referred to as lumpectomy, wherein the surgeon seeks to remove the malignant tumor, while also preserving as much healthy breast tissue as possible.
It is estimated that, each year, as few as 2–3% of cancer patients enter clinical trials. In part I of this series, we discussed four key barriers to participation: physician barriers, protocol barriers, research team barriers, and insurance barriers. In part II, we will look at solutions to these barriers and how to implement them in the clinical setting.
According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1.
Nearly three years after its introduction, the CMS's Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.
